MADRID, September 25, 2017 /PRNewswire/ --
Sylentis presents, for
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
The data will be presented at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) taking place in Bourdeaux, France between the 24th and the 27th of September and where the latest advances in oligonucleotide therapeutics will be presented.
Sylentis has identified NRARP (NOTCH-regulated Ankyrin Repeat Protein) as a potential target for the treatment of angiogenic diseases of the retina. NRARP is a key regulator of the molecular pathways leading to vessel formation; as such, the consequences of modulating the expression of this gene with RNAi has been studied in animal models of retinal neovascularization.
The results of the efficacy studies have shown that reduction of NRARP in the retina using RNAi leads to regression of neovascular lesions and that the lesion reductions observed are equivalent to those observed in response to anti-VEGF treatment, current standard treatment administered by intraocular injection.
Sylentis studies at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society:
Session: September 24th 18:30 to 20:30 horas. Presenting author: Covadonga Paņeda et al. R&D Manager, Sylentis, Espaņa.
Session: September 25th 17:00 to 19:30 horas. Presenting author: Covadonga Paņeda et al. R&D Manager, Sylentis, Espaņa.
Media Contacts: Media Relations (+34-638-79-62-15) Investor Relations (+34-914444500)
Subscribe to our Free Newsletters!
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the ...
Xeroderma pigmentosum is a rare inherited condition marked by extreme sensitivity to sunlight and ...View All